CT-996 Tracker
Roche’s oral GLP-1 — and your protocol today
CT-996 is a once-daily oral small-molecule GLP-1 receptor agonist developed by Roche (acquired through Carmot Therapeutics). It is investigational and not FDA approved. Shotlee is the free app to track your current protocol while the oral GLP-1 field develops.
What is CT-996?
CT-996 is a once-daily oral small-molecule GLP-1 receptor agonist that Roche obtained through its acquisition of Carmot Therapeutics. Like other oral GLP-1 candidates, it aims to deliver GLP-1 weight loss in a daily pill rather than an injection.
It sits alongside Lilly’s orforglipron (Foundayo), Structure Therapeutics’ aleniglipron (GSBR-1290), and AstraZeneca’s AZD5004 in the oral GLP-1 race. Early-phase data has been encouraging, with later-stage trials characterizing efficacy and safety.
CT-996 Key Facts
What to Track in Shotlee
Build clean baseline data now so you can compare if oral GLP-1s reach the market.
Oral GLP-1 Development Outlook
Protocol FAQs
CT-996 is Roche’s once-daily oral small-molecule GLP-1 receptor agonist (from the Carmot Therapeutics acquisition), in clinical development for weight loss and type 2 diabetes. It is investigational and not FDA approved.
Roche, which gained CT-996 by acquiring Carmot Therapeutics. It is one of Roche’s entries in the obesity drug race alongside its injectable CT-388 and petrelintide.
Both are once-daily oral small-molecule GLP-1 agonists but are different molecules from different companies (Roche vs Eli Lilly). They are competing oral GLP-1 candidates; no head-to-head data exists.
It is investigational and only available in trials. Timing depends on later-stage results and regulatory review. Follow Shotlee’s tracker pages for updates.
Yes. Shotlee logs doses, weight, side effects, and labs for your current medication for free, so you have a clean baseline if oral GLP-1s like CT-996 launch.
Track Your Protocol in Shotlee
Free dose logs, weight trends, and side effect tracking — ready for the oral GLP-1 wave.